Department of Pathology, China-Japan Union Hospital, Jilin University, Changchun, Jilin, China.
Department of Urology, The First Hospital of Jilin University, Changchun, Jilin, China.
Bioengineered. 2020 Dec;11(1):572-581. doi: 10.1080/21655979.2020.1765500.
CD44 is reported to be involved in tumor invasion and metastasis. However, the role of cancer stem cell marker CD44 in bladder cancer still remains controversial. Hence, the correlations between CD44 expression and the clinicopathological features and the prognosis of bladder cancer were investigated. Publications using immunohistochemical methods were identified. The Cancer Genome Atlas (TCGA) data were also analyzed. The odds ratios (ORs) or hazard ratios (HRs) with their 95% confidence intervals (95% CIs) were calculated. 14 studies involving 1107 tissue samples were included. CD44 expression in bladder cancer was lower than in non-tumor tissue samples (OR = 0.14, P = 0.005), which was consistent with TCGA data. CD44 expression was correlated with advanced T stage (OR = 1.76, P = 0.029) and lymph node metastasis (OR = 4.09, P < 0.001). Multivariate survival analysis showed that CD44 expression was not linked to tumor-specific survival, overall survival, and recurrence/relapse-free survival, but was associated with disease failure (HR = 2.912, 95% CI = 1.51-5.61). No relationships of CD44 expression with the clinicopathological features and overall survival were found from TCGA data. Our finding suggested that CD44 expression may be correlated with progression, metastasis, and disease failure of bladder cancer. However, further large-scale studies are needed.: CD44: Cluster of Differentiation 44; CIs: Confidence Intervals; CSCs: Cancer Stem Cells; EMT: Epithelial-mesenchymal Transition; HRs: Hazard Ratios; ORs: Odds Ratios; TCGA: The Cancer Genome Atlas.
CD44 据报道与肿瘤侵袭和转移有关。然而，癌症干细胞标志物 CD44 在膀胱癌中的作用仍存在争议。因此，研究了 CD44 表达与膀胱癌临床病理特征和预后的相关性。确定了使用免疫组织化学方法的出版物。还分析了癌症基因组图谱 (TCGA) 数据。计算了比值比 (OR) 或风险比 (HR) 及其 95%置信区间 (95%CI)。纳入了 14 项涉及 1107 个组织样本的研究。膀胱癌中 CD44 的表达低于非肿瘤组织样本 (OR = 0.14，P = 0.005)，与 TCGA 数据一致。CD44 表达与晚期 T 分期 (OR = 1.76，P = 0.029) 和淋巴结转移 (OR = 4.09，P < 0.001) 相关。多变量生存分析表明，CD44 表达与肿瘤特异性生存、总生存和无复发生存无关，但与疾病失败相关 (HR = 2.912，95%CI = 1.51-5.61)。TCGA 数据未发现 CD44 表达与临床病理特征和总生存的关系。我们的研究结果表明，CD44 表达可能与膀胱癌的进展、转移和疾病失败有关。然而，需要进一步的大规模研究。
